肝胆相照论坛

标题: 箭头公司在研究的新药ARO-HBV [打印本页]

作者: 齐欢畅2 时间: 2017-3-19 21:03 标题: 箭头公司在研究的新药ARO-HBV

ARO-HBV is being developed to be a potentially curative therapy for patients with chronic hepatitis B infection. ARO-HBV silences all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this will allow the body’s natural immune defenses to clear the virus and lead to a functional cure.

Disease

Chronic hepatitis B infection is the most common serious liver infection. Current drugs suppress viral replication but rarely lead to a cure and therefore must be taken indefinitely. Developing curative therapy is a priority.

There are 16 million people with chronic hepatitis B in the U.S. and Western Europe and 400 million people worldwide. In the immune tolerant phase of chronic infection, which can last for many years, the infected person typically produces very high levels of viral DNA and viral antigens. However, the infection is not cytotoxic and the carrier may have no symptoms of illness. Over time, the ongoing production of viral antigens causes inflammation and necrosis, leading to cirrhosis and liver cancer (HCC). Hepatitis B is responsible for 80% of primary liver cancers.

The current standard of care for treatment of chronic HBV infection is a daily oral dose of nucleotide/nucleoside analogs (NUCs) or a regimen of interferon injections for approximately one year. NUCs are generally well tolerated, but patients may need lifetime treatment because viral replication often rebounds upon cessation of treatment. Interferon therapeutics can result in a functional cure in around 10% of some patient types, but treatment is often associated with significant side effects, including severe flu-like symptoms, bone marrow suppression, and autoimmune disorders.

作者: 齐欢畅2 时间: 2017-3-19 21:09

抛砖引玉：arc520、521的失败在于仅仅是抑制表抗并不能完全激活免疫系统，乙肝病毒的免疫抑制可能有很多种抗原，或者说，乙肝病毒已经与人体同化了，很难激活免疫。
箭头公司开始了直接激活免疫的治疗策略，关注。（个人观点，不喜勿喷，谢谢！）

作者: newchinabok 时间: 2017-3-19 22:43

本帖最后由 newchinabok 于 2017-3-19 22:44 编辑

回复齐欢畅2 的帖子

俺没看懂洋文，有没有河南版文字

作者: 囧大叔 时间: 2017-3-20 12:19

又要等多久.十年吗?

作者: bigben446 时间: 2017-3-20 15:46

这个公司感觉和重庆啤酒走的一样的路子，股市路线

作者: kite2002005 时间: 2017-3-21 18:55

齐欢畅2 发表于 2017-3-19 21:09
抛砖引玉：arc520、521的失败在于仅仅是抑制表抗并不能完全激活免疫系统，乙肝病毒的免疫抑制可能有很多种 ...

问题是，如果真的是同化了，为何免疫系统有时候还要攻击这个病毒呢？必然是没有真正同化导致的。

作者: newchinabok 时间: 2017-3-21 19:06

这个项目还在临床前

作者: newchinabok 时间: 2017-3-21 19:07

这个项目还在
临床前

作者: hao2014 时间: 2017-3-21 19:23

这个路子起码5年以上才能初步有分晓

作者: csfluke 时间: 2017-3-21 19:30

看了下箭头公司的股票，从520项目中止后暴跌的谷底1块2反弹到2块了，不过离巅峰的9块7还有遥远的距离，看来新药还只是刚起步。

作者: 商业战士 时间: 2017-3-21 20:37

遥遥无期，希望是认真研究，哪怕失败也行。就怕是重庆啤酒式吹故事。

作者: MP4 时间: 2017-3-21 20:46

商业战士发表于 2017-3-21 20:37
遥遥无期，希望是认真研究，哪怕失败也行。就怕是重庆啤酒式吹故事。

重庆啤酒也好，剪头也好，都是认真研究的，从来就没有吹过

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)